Systems Bio
Drug development is a highly rewarding yet inherently risky process, beginning with target selection. Choosing an incorrect drug target can result not only in significant financial losses but, more critically, in the loss of valuable time. This can cause irreparable harm to pharmaceutical companies and, most importantly, patients. This risk can be significantly mitigated through well-strategized data-driven approaches to target selection and validation.
Recent unprecedented advances in high throughput technologies enabled generation of molecular omics data at large scale. These technologies provide highly accurate insights into the molecular landscape for drug target selection and validation. To fully leverage these extensive datasets, a strong background in Data Science associated with extensive Biomedical expertise is indispensable.
The mission of Systems Biology Consulting & Analytics (Systems Bio) is to accelerate clinical and translational discoveries by guiding pharmaceutical enterprises to harness the power of molecular data. To achieve this, Systems Bio supports pharmaceutical enterprises of all sizes in planning experiments, as well as generating, analyzing and interpreting omics data to discover and validate new and existing drug targets.
Reach out to us to learn about the ways how Systems Bio can help your life sciences organization to leverage genomics data for new discoveries.